Canyon Labs Expands With iuvo Acquisition To Boost Lab Services

Canyon Labs is a global leader in analytical and packaging lab testing for medical devices and pharmaceuticals. The company has strategically acquired iuvo BioScience’s laboratory services and scientific consulting divisions. This move helps both companies to strengthen and position themselves for accelerated growth in their specialities.

Canyon Labs gains iuvo’s renowned lab services and consulting expertise through the agreement, enhancing its ability to provide end-to-end pharmaceutical and medical device development solutions. Meanwhile, iuvo BioScience will sharpen its focus on ophthalmic clinical research, retaining its clinical research team and leadership structure to advance transformative eye-care innovations.

Sarah (Rosenblum) Ptach, President of Canyon Labs, said in a statement, “This acquisition marks a significant milestone in the growth of Canyon Labs’ capacity and capabilities.  By strategically aligning our organisations, we deliver immediate value to our global client base through faster lead times, expanded capacities, and unparalleled expertise at every process step. This integration strengthens our commitment to raising the standard of service in outsourced testing and consulting for the healthcare industry.”

The acquisition expands Canyon Labs’ presence to Rochester, NY, complementing its existing facilities in Salt Lake City, UT (headquarters) and San Diego, CA. The Rochester site adds cutting-edge capabilities in rapid sterility testing, in vitro and in vivo biocompatibility, microbiology, and analytical chemistry. Backed by MedVenture Health, Canyon Labs continues to grow its expertise and offerings, strengthened by its experienced leadership team, including David Kudla, Donnalee Ventura, Nancy Rakiewicz, and Christopher Dietz.

Ben Burton, President and CEO of iuvo BioScience, commented, “This transaction marks a defining moment for iuvo. This strategic decision reinforces our fundamental mission of accelerating patient access to breakthrough vision care treatments. By sharpening our focus on our ophthalmic clinical contract research business, we’re strengthening our ability to provide the high touch, science-driven solutions our customers and partners have come to expect from iuvo.”

For iuvo BioScience, this transaction follows its acquisition of Promedica International (PMI) in early 2024. Under the continued leadership of Shannon Stoddard, iuvo’s President of Clinical Research, the company is set to expand its ophthalmic clinical contract research services for both anterior and posterior segment conditions. Supported by Ampersand Capital Partners, iuvo BioScience aims to solidify its position as a global leader in ophthalmic clinical research.